Helvia Tablets / Film-coated
Dienogest, Ethinylestradiol
"2mg, 0.03mg"
JUSTE, S.A. QUIMICO-FARMACEUTICA
| Pack size | 28's Blister [21 active +7 Placebo] |
|---|---|
| Dispensing mode | PhOM |
| Source | SPAIN |
| Agent | NEW MEDICAL CENTRE |
| Retail Price | 41.00 AED |
Indications
Helvia Tablets / Film-coated is used for:
Dienogest
Indicated for use as the treatment of endometriosis alone and as a contraceptive in combination with ethinylestradiol.
Ethinylestradiol
For treatment of moderate to severe vasomotor symptoms associated with the menopause, female hypogonadism, prostatic carcinoma-palliative therapy of advanced disease, breast cancer, as an oral contraceptive, and as emergency contraceptive.
Indicated for use as the treatment of endometriosis alone and as a contraceptive in combination with ethinylestradiol.
Ethinylestradiol
For treatment of moderate to severe vasomotor symptoms associated with the menopause, female hypogonadism, prostatic carcinoma-palliative therapy of advanced disease, breast cancer, as an oral contraceptive, and as emergency contraceptive.
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Dienogest, Ethinylestradiol :
Mechanism of Action
Dienogest
Dienogest acts as an agonist at the progesterone receptor (PR) with weak affinity that is comparable to that of progesterone but has a very potent progestagenic effect in the endometrium, causing endometrial atrophy after prolonged use [A20331]. It promotes antiproliferative, immunologic and antiangiogenic effects on endometrial tissue. Dienogest reduces the level of endogenous production of oestradiol and thereby suppressing the trophic effects of oestradiol on both the eutopic and ectopic endometrium [L932]. Continous administration of dienogest results in hyperprogestogenic and moderately hypoestrogenic endocrine environment, which causes initial decidualization of endometrial tissue [L931]. It is an antagonist at androgen receptors, improve androgenic symptoms such as acne and hirsutism [A16570].
Ethinylestradiol
Estrogens diffuse into their target cells and interact with a protein receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. This cascade is initiated by initially binding to the estrogen receptors. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (GnRH).
Dienogest acts as an agonist at the progesterone receptor (PR) with weak affinity that is comparable to that of progesterone but has a very potent progestagenic effect in the endometrium, causing endometrial atrophy after prolonged use [A20331]. It promotes antiproliferative, immunologic and antiangiogenic effects on endometrial tissue. Dienogest reduces the level of endogenous production of oestradiol and thereby suppressing the trophic effects of oestradiol on both the eutopic and ectopic endometrium [L932]. Continous administration of dienogest results in hyperprogestogenic and moderately hypoestrogenic endocrine environment, which causes initial decidualization of endometrial tissue [L931]. It is an antagonist at androgen receptors, improve androgenic symptoms such as acne and hirsutism [A16570].
Ethinylestradiol
Estrogens diffuse into their target cells and interact with a protein receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. This cascade is initiated by initially binding to the estrogen receptors. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (GnRH).
Note
Helvia "2mg, 0.03mg" Tablets / Film-coated manufactured by JUSTE, S.A. QUIMICO-FARMACEUTICA. Its generic name is Dienogest, Ethinylestradiol. Helvia is availble in United Arab Emirates.
Farmaco UAE drug index information on Helvia Tablets / Film-coated is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.